bluebird bio Announces Pricing of Initial Public Offering

bluebird bio Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 18, 2013-- 

bluebird bio, Inc., a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced the pricing of its initial public offering of 5,941,176 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts. All of the common stock is being offered by bluebird bio. In addition, the underwriters have a 30-day option to purchase up to an additional 891,176 shares of common stock from bluebird bio. The company's shares are expected to begin trading on The NASDAQ Global Select Market on Wednesday, June 19, 2013 under the trading symbol "BLUE."

J.P. Morgan Securities LLC and BofA Merrill Lynch are acting as joint book-running managers for the offering. Cowen and Company is acting as lead manager and Canaccord Genuity Inc. and Wedbush PacGrow Life Sciences are acting as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 18, 2013. When available, copies of the final prospectus relating to this offering may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (866) 803-9204, or from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

 
    CONTACT: Investor Relations: 

bluebird bio, Inc.

Richard E. T. Smith, Ph.D., 919-588-3321

[email protected]

or

Media Contact:

Pure Communications, Inc.

Dan Budwick, 973-271-6085

[email protected]

 
    SOURCE: bluebird bio, Inc. 

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.